12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Calcitonin salmon regulatory update

FDA's Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee will meet on March 5 to discuss whether the benefit of calcitonin salmon for postmenopausal osteoporosis outweighs a potential risk of...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >